Health Care • Medical/Dental Instruments
$3.27 ▲ +0.10
(+3.16%)
MKT CAP: $35.5M • VOL: 72.4K
52W L $3 52W H $6
ROARABLE / RQD
B • 73/100
PIOTROSKI
8 / 9
NEPH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $18.8M | $14.2M | $14.2M |
| YoY Revenue Growth % | +32.7% | -0.5% | — |
| Gross Profit | $11.6M | $8.7M | — |
| Gross Margin % | 61.9% | 61.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.1M | $6.0K | -$1.6M |
| Operating Margin % | 6.1% | 0.0% | -11.2% |
| Net Income (GAAP) | $1.2M | $74.0K | -$1.6M |
| EBITDA (Normalized) | — | $50.0K | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.6M | -$492.0K | $827.0K |
| Capital Expenditures (CapEx) | — | $55.0K | — |
| Free Cash Flow (FCF) | $1.6M | -$547.0K | $827.0K |
| FCF Margin % | 8.5% | -3.9% | 5.8% |
| Return on Invested Capital (ROIC %) | 18.9% | 0.1% | — |
| Cash & Short-Term Equivalents | $5.4M | $3.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $10.2M | $8.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NEPH.